Short url
In a video released on April 20, Didier Rawold states that there are “70% side effects” with the Pfizer / Bioentech vaccine, based on an article published in the February 16 issue of the American journal Nature. 20 minutes describes it as an unstable pain felt at the injection site.
A stimulus The video was released on April 20 Sections of people who need priority for the vaccine, Didier Rawold reports “70% side effects” with the Pfizer / Bioentech vaccine based on an article published in the American Journal of Science on February 16 Natural.
However, this reveals it These side effects Not severe in any way, and causes pain at the site of the sting.
Review indicates Data by Tom Shimabukuro, Dated January 14 U.S. A part of the Centers for Disease Control and Prevention (CDC) in the U.S. Researcher at the National Center for Immunization and Respiratory Diseases.
Of the nearly one million people who participated in the research, 67.7% experienced pain after the first injection of the Pfizer / BioNTech vaccine, followed by 74.8%.
Data recorded in March showed only a small difference: 72.9% after the first dose and 79.3 after the second.
28.6% felt tired after the first dose. The percentages for headaches were 26 and 42, respectively.
Effects of mild or moderate intensity
“Generally, Vaccine protection Govit-19 [Pfizer/BioNTech et Moderna] Quoted by Tom Shimabukuro for 20 minutes.
In clinical trials, the CDC found that 77.4% of participants who had a symptomatic diary seven days after vaccination reported at least one side effect. The majority are “mild or moderate in intensity”.
Edward Langley is a contributor to Nintendo-power.com, covering a wide range of topics including news, business, technology, entertainment, lifestyle and current affairs. He focuses on delivering clear, balanced and accessible reporting that helps readers stay informed about important developments and emerging trends. With an emphasis on accuracy, relevance and useful insights, Edward aims to provide engaging stories and practical information that matter to audiences in the UK and beyond.